Barclays PLC Has $116,000 Stock Holdings in Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Barclays PLC grew its stake in Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 281.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,288 shares of the company’s stock after buying an additional 6,855 shares during the period. Barclays PLC’s holdings in Gyre Therapeutics were worth $116,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC acquired a new stake in shares of Gyre Therapeutics in the third quarter valued at about $47,000. Rhumbline Advisers acquired a new stake in shares of Gyre Therapeutics in the second quarter valued at about $123,000. Renaissance Technologies LLC acquired a new stake in shares of Gyre Therapeutics in the second quarter valued at about $166,000. Bank of New York Mellon Corp acquired a new stake in shares of Gyre Therapeutics in the second quarter valued at about $218,000. Finally, WINTON GROUP Ltd acquired a new stake in shares of Gyre Therapeutics in the second quarter valued at about $220,000. Institutional investors and hedge funds own 23.99% of the company’s stock.

Insider Activity at Gyre Therapeutics

In related news, President Songjiang Ma sold 2,000 shares of the company’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00. Following the sale, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. This represents a 0.07 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 12,941 shares of company stock worth $153,041 in the last 90 days. Corporate insiders own 19.52% of the company’s stock.

Gyre Therapeutics Price Performance

Shares of GYRE stock opened at $9.62 on Thursday. The stock has a 50-day moving average of $12.20 and a 200-day moving average of $12.65. Gyre Therapeutics, Inc. has a 1-year low of $8.26 and a 1-year high of $27.10.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.